Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21025711 | 0.88 | CHRM2 (0.36) | TSHRHCRTR2CHRM2CHRM1CHRM4 | |
| SCHEMBL177205 | 0.83 | — | — | |
| SCHEMBL12476221 | 0.83 | CHRM2 (0.42) | TSHRCHRM2CHRM1CHRM4CHRM3 | |
| SCHEMBL10710365 | 0.83 | HCRTR2 (0.33) | HCRTR2 | |
| SCHEMBL27563919 | 0.81 | — | — | |
| Ammonia Solution, Strong SCHEMBL28770241 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL28064630 | 0.81 | — | — | |
| SCHEMBL28780475 | 0.81 | — | — | |
| SCHEMBL5439131 | 0.81 | HCRTR2 (0.35) | HCRTR2 | |
| SCHEMBL18082716 | 0.81 | ATM (0.41) | HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759781-B2 | Substituted guanidine derivatives | UBE INDUSTRIES, LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| US-20190152953-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | UBE INDUSTRIES, LTD. (JP) | 2019-05-23 | — | — | US | disclosed |
| US-7825149-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2010-11-02 | — | — | US | disclosed |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-7592362-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-7585864-B2 | Farnesyl protein transferase inhibitors and their use to treat cancer | SCHERING CORPORATION (US) | 2009-09-08 | — | — | US | disclosed |
| US-7547718-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| US-7544706-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-22 | — | — | US | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| CN-1170811-C | Inhibitors of branched chain amino acid dependent aminotransferases and their use in the treatment of diabetic retinopathy | ��ʲ | 2004-10-13 | — | — | CN | disclosed |
| CN-1344245-A | Inhibitors of branched chain amino acid dependent aminotransferases and their use in the treatment of diabetic retinopathy | WARNER LAMBER CO (US) | 2002-04-10 | — | — | CN | disclosed |
| EP-0196222-B1 | HYPOGLYCEMIC AGENT | AJINOMOTO CO., INC. (JP) | 1992-01-29 | — | — | EP | disclosed |
| EP-0196222-A2 | Hypoglycemic agent | AJINOMOTO CO., INC. (JP) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | TSHR 3443/4885HCRTR2 4529/4885CHRM2 831/4885 |
| US-20090312326-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | TSHR 3443/4885HCRTR2 4529/4885CHRM2 831/4885 |
| US-10759781-B2 | Substituted guanidine derivatives | GMPS, GUCY1A1, GUCY1A2 | TSHR 1808/4885HCRTR2 3203/4885CHRM2 103/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | TSHR 3443/4885HCRTR2 4529/4885CHRM2 831/4885 |
| US-20080119536-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | TSHR 3443/4885HCRTR2 4529/4885CHRM2 831/4885 |
| US-20190152953-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | GMPS, GUCY1A1, GUCY1A2 | TSHR 1808/4885HCRTR2 3203/4885CHRM2 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.